Nature Comm’s article (Orpheus – StratifAI)
Artificial Intelligence in Breast Cancer Diagnostics – Another Scientific Achievement of MultiplexDX
MultiplexDX International has reached another significant scientific milestone. In collaboration with leading experts from universities and oncology institutes in New York, Dresden, Milan, Heidelberg,and Erlangen, we have published a research article in the prestigious journal Nature Communications. This marks our second publication in this renowned journal in 2025.
In the article, we introduce anew computational test called Orpheus, which utilizes multimodal artificial intelligence to predict the risk of breast cancer recurrence in women more accurately. Orpheus analyzes routinely available histological slides(H&E) and pathology reports, offering a faster, more accessible, and cost-effective solution compared to the widely used Oncotype DX Breast Recurrence Score® test.
The Orpheus test was developed and validated using 6,172 patient samples, accurately identifying patients at high risk of disease recurrence and significantly outperforming Oncotype DX in assessing metastatic risk among patients who would not usually receive chemotherapy. Whether Orpheus proves to be more precise than OncotypeDX will be determined by further prospective clinical validation.
MultiplexDX strongly believes in the potential of the StratifAI team, led by Omar El Nahhas, which developed the test. Together with the Slovak venture fund Neulogy Ventures, we invested in StratifAI, which is now among the most innovative and fastest-growing startups in Europe.
Our ambition is to see AI-driven solutions extend to other types of cancer in the future, contributing to the advancement of personalized medicine that can identify the most effective treatment for each patient.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
